Durect rated overweight by Global Crown

Global Crown Capital, LLC maintained its overweight rating for Durect Corp. in anticipation of the release of phase-three clinical data for Saber bupivacaine, a long-acting local anesthetic. Analyst Kate Winkler expected a positive response from surgeons and investors and described Durect as having lower-risk product development hurdles than comparable biotech companies, with comparable or greater upside.

Shares of the Cupertino, Calif.-based pharmaceutical company were up $0.43, or 6.67%, at $6.88 on volume of 435,760 shares versus a three-month running average of 363,630 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.